THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $4,276,000 | +603.3% | 577,800 | +1450.8% | 0.40% | +35.7% |
Q2 2019 | $608,000 | -89.3% | 37,258 | -92.8% | 0.30% | -69.0% |
Q3 2015 | $5,680,000 | -10.6% | 516,804 | +5.9% | 0.96% | +8.4% |
Q2 2015 | $6,354,000 | +50.3% | 487,992 | +100.2% | 0.88% | +39.7% |
Q1 2015 | $4,228,000 | +13.1% | 243,706 | -2.7% | 0.63% | +9.1% |
Q4 2014 | $3,738,000 | – | 250,550 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |